<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26379753</article-id><article-id pub-id-type="pmc">4561327</article-id><article-id pub-id-type="doi">10.1155/2015/910376</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiu-min</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Run-yue</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Qing-chun</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor2">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Yong-liang</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Jing-yao</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Rheumatology, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China</aff><aff id="I2"><sup>2</sup>Postdoctoral Mobile Research Station, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China</aff><author-notes><corresp id="cor1">*Run-yue Huang: <email>ry_huang@hotmail.com</email> and </corresp><corresp id="cor2">*Qing-chun Huang: <email>qch1963@163.com</email></corresp><fn fn-type="other"><p>Academic Editor: Kamal D. Moudgil</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>24</day><month>8</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>910376</elocation-id><history><date date-type="received"><day>20</day><month>1</month><year>2015</year></date><date date-type="rev-recd"><day>10</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Xiu-min Chen et al.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Chinese medicines are gaining wider acceptance. They have been used for treating rheumatoid arthritis (RA) for thousands of years, and the need to investigate the interaction between Chinese medicines and western medicines is widely recognized. In this study, a large number of RCTs and CCTs were analyzed to systematically assess the effects and adverse events of Zhengqing Fengtongning (ZQFTN) for RA. Eleven studies that contained 956 participants (508 in the treatment group; 448 in the control group) were included. The results showed that although ZQFTN combined with methotrexate MTX could not decrease the swollen joint count and tender joint count of RA patients better than MTX alone, the combination therapy might relieve the duration of morning stiffness (SMD: &#x02212;16.06; 95% CI: &#x02212;28.77 to &#x02212;3.34), reduce laboratory indexes (RF: SMD: &#x02212;10.84; 95% CI: &#x02212;19.39 to &#x02212;2.29; ESR: SMD: &#x02212;7.26; 95% CI: &#x02212;11.54 to &#x02212;2.99; CRP: SMD: &#x02212;3.66; 95% CI: &#x02212;5.94 to &#x02212;1.38), and improve the overall effect (RR: 1.08; CI: 1.01 to 1.16) better than monotherapy. The combination therapy was significantly better in controlling adverse drug reactions (RR: 0.60; 95% CI: 0.46 to 0.79). Through this systematic review, we found that ZQFTN combined with MTX for the treatment of RA might have better clinical efficacy than MTX only and might be superior in terms of controlling adverse drug reactions.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, characterized by inflammation of the synovial tissue and damage to articular cartilage and bone leading to severe disability, functional decline, and accelerated mortality [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. RA is the most common inflammatory rheumatic disease, with a prevalence of 0.5%&#x02013;1.0% in Europe and North America. In Southeast Asia, including Japan and China, the prevalence is slightly lower, accounting for 0.2%-0.3% [<xref rid="B3" ref-type="bibr">3</xref>]. In China, up to 5 million people suffer from RA [<xref rid="B4" ref-type="bibr">4</xref>], which imposes a considerable burden on patients, their families, and society. Treatment options for RA include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), local steroids, and biologics. Methotrexate (MTX), one of the DMARDs, is the first-line drug for treating RA [<xref rid="B5" ref-type="bibr">5</xref>]. The treatment methods do not retard or stop the radiographic progression or prevent joint damage. Some studies have demonstrated that 30% of the patients in remission had radiographic progression, 96% had synovitis, and 35% had osteitis [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Drug toxicity, high costs, and lack of long-term safety data are, to some extent, inevitable problems for application of the current therapeutic strategies. These factors lead to the use of complementary and alternative medicines (CAMs), including meditation, acupuncture, chiropractic, vitamin and mineral therapy, herbal medicine, and hypnotherapy.</p><p>Alternatively, Chinese medicine could be a viable treatment option because it has been used to treat human diseases in China and other parts of the world for thousands of years. Chinese medicine could effectively treat RA with a low adverse reaction [<xref rid="B8" ref-type="bibr">19</xref>]. Sinomenine (SIN) was isolated from<italic> Sinomenium acutum</italic>, a Chinese medicinal plant that has been used for treating rheumatoid diseases including RA for over 2000 years [<xref rid="B9" ref-type="bibr">20</xref>, <xref rid="B10" ref-type="bibr">21</xref>]. SIN has a variety of pharmacological effects including analgesia, anti-inflammatory properties, and immune suppression [<xref rid="B11" ref-type="bibr">22</xref>]. Zhengqing Fengtongning (ZQFTN), as a SIN preparation, has been used for treating RA for many years. As ZQFTN is used with increasing frequency, the need to investigate the interactions between ZQFTN and western drugs is widely recognized. In this paper, we performed a systematic review with meta-analysis of randomized controlled trials that compared ZQFTN in combination with MTX with MTX monotherapy. The objective of this study was to determine whether ZQFTN combined with MTX is superior and safer than MTX monotherapy for treating RA. We hypothesized that the results of this systematic review could summarize the available evidence for clinicians to RA treatment using SIN preparations.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><p>This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to ensure its accuracy [<xref rid="B12" ref-type="bibr">23</xref>].</p><sec id="sec2.1"><title>2.1. Search Strategy</title><p>A systematic review was conducted by searching multiple databases including Medline/PubMed, Embase, the China National Knowledge Infrastructure (CNKI), the Chinese Medical Journal Database, Wanfang Data, VIP, the Chinese Biomedical Literature Database, the Chinese Scientific and Technological Journals Database, the Traditional Chinese Medicine Database, the China Doctorate Dissertation Full Text Database, and other databases. The databases were searched from their start date to December 2013. For the English databases, free text terms such as &#x0201c;Sinomenine&#x0201d; or &#x0201c;<italic>Sinomenium</italic>&#x0201d; or &#x0201c;Zhengqing Fengtongning&#x0201d; and &#x0201c;rheumatoid arthritis&#x0201d; or &#x0201c;RA&#x0201d; were used. For the Chinese databases, free text terms such as &#x0201c;qing feng teng&#x0201d; or &#x0201c;qing teng jian&#x0201d; or &#x0201c;Zhengqing Fengtongning&#x0201d; and &#x0201c;lei feng shi guan jie yan&#x0201d; or &#x0201c;pain paralysis&#x0201d; were used. The languages were limited to English or Chinese. A secondary search was conducted, and ambiguous literature was searched as well.</p></sec><sec id="sec2.2"><title>2.2. Selection Criteria</title><p>Randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that involved the efficacy and/or safety of ZQFTN to treat RA were selected. The studies were selected for analysis if they satisfied the following criteria. (1) The subjects took ZQFTN combined with MTX versus MTX only. (2) The included participants were patients with a clear diagnosis of RA. The diagnostic criteria for RA in the trials accorded with the American Rheumatism Association 1987 revised criteria for the classification of RA [<xref rid="B13" ref-type="bibr">24</xref>]. (3) ZQFTN was used as an active treatment intervention. (4) There were no restrictions regarding sex, age, severity, and duration of RA.</p></sec><sec id="sec2.3"><title>2.3. Outcome Assessment</title><p>The outcome measures included enumeration data and measurement data. The enumeration data pertained to the clinical efficacy and adverse events. The number of patients treated effectively in each group was counted based on the categories of cured, markedly effective, and effective. The measurement data included rheumatoid factor (RF), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), and duration of morning stiffness (DMS).</p></sec><sec id="sec2.4"><title>2.4. Data Extraction</title><p>Three authors participated in the data extraction of all the studies included in the review. Two authors (Xiumin Chen and Runyue Huang) first extracted the relevant data including the first author, publication year, total number of cases included in the experimental group (EG) and the control group (CG), intervention methods, and endpoint evaluation indicators, independently. Disagreements were resolved by consensus or were arbitrated by the third author (Qingchun Huang).</p></sec><sec id="sec2.5"><title>2.5. Quality Assessment of the Included Studies</title><p>The quality of each study included in this review was assessed using the Cochrane Handbook for Systematic Reviews of Interventions and Jadad scoring [<xref rid="B14" ref-type="bibr">25</xref>]. The details that were assessed were as follows: (1) whether the test methods were random, (2) whether allocation concealment was achieved, (3) whether blinded tests were adopted, and (4) whether patients were lost because of follow-up or quitting. Scoring of 1&#x02013;3 indicated low quality, whereas 4&#x02013;7 indicated high quality [<xref rid="B15" ref-type="bibr">26</xref>].</p></sec><sec id="sec2.6"><title>2.6. Statistical Methods</title><p>Review Manager (Revman) (Computer program), version 5.3. (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014), was used to analyze the collected clinical research data. The enumeration data were evaluated using the relative risk (RR) and 95% confidence interval (CI), and the measurement data were combined using the standardized mean difference (SMD) and 95% CI. Analysis was carried out using a fixed or random effects model according to the heterogeneity. The percentage of heterogeneity in the study was determined by the <italic>I</italic>
<sup>2</sup> statistic, with a value of 0% indicating no heterogeneity and larger values indicating increased heterogeneity. A <italic>P</italic> value &#x0003c;0.10 was considered to suggest statistical heterogeneity and prompted random effects modelling.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Literature Search Results</title><p>Using the search strategy, 300 studies were retrieved. After removal of duplicates across databases, 164 studies were screened. From the 164 studies, 11 studies that met the inclusion criteria were included in this study for the systematic review [<xref rid="B16" ref-type="bibr">8</xref>&#x02013;<xref rid="B26" ref-type="bibr">18</xref>]. The study selection process is shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. The characteristics of the studies are summarized in <xref ref-type="table" rid="tab1">Table 1</xref>. These studies included a total of 956 participants, 508 in the treatment group and 448 in control group. The duration of most studies was 12 or 24 weeks. The dose of MTX in the combination therapy groups ranged between 7.5 and 10&#x02009;mg/week except for one study (15&#x02009;mg/week) [<xref rid="B18" ref-type="bibr">10</xref>], while the dose was larger in the monotherapy groups, ranged between 10 and 15&#x02009;mg/week. The doses of ZQFTN ranged between 60 and 240&#x02009;mg/day but most were 120&#x02009;mg/day.</p></sec><sec id="sec3.2"><title>3.2. Quality of Included Systematic Studies</title><p>Most of the included studies were of low quality because of unclear randomization, inefficient allocation concealment, inadequate blinding, or described withdrawals and dropouts. The high-quality studies accounted for 27.27% (3/11) of the total studies. In addition, 90.91% (10/11) of the studies mentioned a random and blinded design, and only 18.18% (2/11) described the random design; 9.09% (1/11) described the dropouts, whereas 90.91% (10/11) of the studies failed to mention the number of patients who quit the study or were lost during follow-up (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p></sec><sec id="sec3.3"><title>3.3. Total Effect of ZQFTN</title><p>The 11 studies were analyzed for comparisons of the total effect of ZQFTN combined with MTX and of MTX only. The data indicated that 472 patients (92.91%) improved after treatment with ZQFTN combined with MTX whereas 375 patients (83.71%) improved after treatment with MTX only. The meta-analysis was performed using a random effects model because of the high heterogeneity (<italic>I</italic>
<sup>2</sup> = 70%, <italic>P</italic> &#x0003c; 0.10). The combined RR was 1.08, and the 95% CI was 1.01 to 1.16 (<italic>P</italic> = 0.02), indicating that ZQFTN combined with MTX was better in improving the overall symptoms of RA patients than MTX only (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="sec3.4"><title>3.4. Rheumatoid Factor (RF)</title><p>Eight studies including 758 patients (409 in the experimental group and 349 in the control group) provided the serum RF concentration data. The <italic>I</italic>-squared was 86% and the <italic>P</italic> value was &#x0003c;0.10 indicating high heterogeneity, so a random effects model was adopted for the meta-analysis. The combined SMD was &#x02212;10.84 with a 95% CI of &#x02212;19.39 to &#x02212;2.29 (<italic>P</italic> = 0.01). Therefore, ZQFTN combined with MTX and MTX showed significant differences in reducing the serum RF concentration in RA patients (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p></sec><sec id="sec3.5"><title>3.5. Erythrocyte Sedimentation Rate (ESR) (mm/h)</title><p>Ten studies provided ESR data, and a random effects model was used for the analysis. The combined SMD was &#x02212;7.26, and the 95% CI ranged from &#x02212;11.54 to &#x02212;2.99 (<italic>P</italic> &#x0003c; 0.01). There was an obvious difference between the effects of ZQFTN combined with MTX and of MTX alone in reducing the ESR (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p></sec><sec id="sec3.6"><title>3.6. C-Reactive Protein (mg/L)</title><p>Eight studies provided the C-reactive protein data. The meta-analysis showed that <italic>I</italic>
<sup>2</sup> = 93% which meant high heterogeneity and the analysis was performed using a random effects model. The combined SMD was &#x02212;3.66, and the 95% CI ranges from &#x02212;5.94 to &#x02212;1.38 (<italic>P</italic> &#x0003c; 0.01). Significant differences were found in the reduction of serum CRP levels between the group of ZQFTN combined with MTX and the MTX group (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p></sec><sec id="sec3.7"><title>3.7. Duration of Morning Stiffness, Swollen Joint Count, and Tender Joint Count</title><p>The duration of morning stiffness, swollen joint count, and tender joint count were analyzed in this review, and random effects models were adopted for the three analyses. <xref ref-type="fig" rid="fig7"> Figure 7</xref> shows the results of the meta-analyses on the duration of morning stiffness. The data indicated that ZQFTN combined with MTX and MTX only showed significant differences in their ability to reduce the duration of morning stiffness in RA patients (SMD: &#x02212;16.06; 95% CI: &#x02212;28.77 to &#x02212;3.34; <italic>P</italic> = 0.01). <xref ref-type="fig" rid="fig8"> Figure 8</xref> shows the result of the meta-analysis on swollen joint count. The combined SMD was &#x02212;0.19, and the 95% CI ranged from &#x02212;1.22 to 0.84 (<italic>P</italic> = 0.72), indicating that there were no statistical significances between the effects of ZQFTN combined with MTX and MTX alone on reducing the swollen joint count. <xref ref-type="fig" rid="fig9"> Figure 9</xref> presents the results of the meta-analyses on tender joint count. It shows that no differences were found on the ability of reducing the tender joint count between the group of ZQFTN combined with MTX and the MTX group (SMD: &#x02212;0.71; 95% CI: &#x02212;1.97 to &#x02212;0.56; <italic>P</italic> = 0.27).</p></sec><sec id="sec3.8"><title>3.8. Adverse Effects (AEs)</title><p>Ten studies provided AEs, including 64 patients (13.42%) in the experimental group and 101 (24.16%) in the control group. The analysis was performed using a fixed effects model because there had been no heterogeneity (<italic>I</italic>
<sup>2</sup> = 0%). The results show that there were fewer adverse reactions overall when using ZQFTN combined with MTX to treat RA than when using MTX alone (RR: 0.60; 95% CI: 0.46 to 0.79; <italic>P</italic> &#x0003c; 0.01) (<xref ref-type="fig" rid="fig10">Figure 10</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Although one systematic review and meta-analysis regarding the efficacy and safety of SIN in the treatment of RA have been reported, the systematic review is dated and it examined SIN versus NSAIDs for the treatment of RA [<xref rid="B27" ref-type="bibr">27</xref>]. It concluded that SIN preparations might possess an efficacy comparable to that of NSAIDs for ameliorating patients' major symptoms or signs as well as laboratory markers [<xref rid="B27" ref-type="bibr">27</xref>]. Nevertheless, as a therapeutic agent of RA, SIN could inhibit the development and progression of CIA in rats [<xref rid="B28" ref-type="bibr">28</xref>], might inhibit bFGF-induced angiogenesis in vitro and in vivo [<xref rid="B29" ref-type="bibr">29</xref>], could induce the apoptosis of macrophages through activation of the ERK pathway, and inhibit proliferation and induce apoptosis via activation of caspase 3 of CD4<sup>+</sup> T cells [<xref rid="B30" ref-type="bibr">30</xref>]. In recent years, studies showed that the imbalance of T helper 17 (Th17)/T regulatory (Treg) cells played a crucial role in RA [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>], while SIN could regulate the balance of Th17/Treg cells in arthritis rats [<xref rid="B32" ref-type="bibr">32</xref>]. Therefore, SIN may be as herb DMARDs because of its immunomodulatory and anti-inflammatory activities to treat RA combined with MTX. Many regimens on SIN combined with MTX in the treatment of RA have been studied, but the relative benefit and toxicity of SIN combined with MTX versus monotherapy are not clear.</p><p>In our study, the efficacy and safety of ZQFTN combined with MTX versus MTX only for treating RA were reviewed. According to this study, 11 studies met the diagnosis as well as the inclusion and exclusion criteria, including 956 patients (508 in the treatment group and 448 in the control group). Revman 5.3 software was used for the data syntheses and meta-analyses. The results showed that ZQFTN combined with MTX had a better total effect than MTX alone. A statistically significant difference was shown in the reduction of the serum RF, ESR, and CRP levels of the RA patients between the 2 groups. The result in <xref ref-type="fig" rid="fig7">Figure 7</xref> indicates that the combination therapy had a better effect than the monotherapy on reducing the clinical symptoms of morning stiffness duration. However, the ZQFTN groups and MTX groups showed a similar effect in the reduced numbers of swollen joints and tender joints in the patients with RA. Although ZQFTN combined with MTX could not decrease the swollen joint count and tender joint count of RA patients more than MTX only, the combination therapy might decrease the duration of morning stiffness, reduce the laboratory indexes, and improve the overall effect more effectively than monotherapy. <xref ref-type="table" rid="tab1">Table 1</xref> shows that the dose of MTX in combination therapy is smaller than that in monotherapy in most of the studies, indicating that combination therapy may reduce the dose of synthetic DMARDs.</p><p>The meta-analysis showed that there was a statistically significant difference in the total AEs. The most common AEs of the two groups were gastrointestinal discomfort, abnormal liver function, skin discomfort, blood cell reduction, menstrual disorders, dizziness, and amenorrhea. These AEs could be relieved with or without treatment and there were no withdrawals due to AEs.</p><p>The limitations of this meta-analysis should be noted. All of the included studies described above were performed in China because standardized ZQFTN was not available outside of China, and the basic and clinical effects of ZQFTN in other countries might not be consistent with these data. Many of the studies included a small number of patients. The journals in which these studies were published are of poor quality. The most important criteria, including ACR 20, ACR 50, and ACR 70, were not reported in all of the studies. Accordingly, the conclusions of this review should be carefully interpreted. Because of the increasing use of Chinese medicines, accurate data on the interactions between Chinese medicines and western medicines are required.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>Through a systematic review of the clinical efficacy and safety of ZQFTN combined with MTX versus MTX only for the treatment of RA, we found that ZQFTN combined with MTX might have better clinical efficacy than MTX only for the treatment of RA. A small dose ZQFTN combined with MTX was superior to MTX alone for controlling adverse drug reactions. ZQFTN, as a type of herbal DMARD, appears to have higher effects and lower side effects than synthetic DMARDs. Considering the low methodological quality of the randomized trials, more RCTs are needed before ZQFTN could be recommended to replace or be combined with synthetic DMARDs.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors thank the authors of the original studies that they included in their meta-analysis.</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declared that there is no conflict of interests.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McInnes</surname><given-names>I. B.</given-names></name><name><surname>Kim</surname><given-names>H.-Y.</given-names></name><name><surname>Lee</surname><given-names>S.-H.</given-names></name><etal/></person-group><article-title>Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study</article-title><source><italic>Annals of the Rheumatic Diseases</italic></source><year>2014</year><volume>73</volume><issue>1</issue><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202442</pub-id><pub-id pub-id-type="other">2-s2.0-84889645613</pub-id><pub-id pub-id-type="pmid">23482473</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.-H.</given-names></name><name><surname>Rajaiah</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>D. Y.-W.</given-names></name><etal/></person-group><article-title>Suppression of ongoing experimental arthritis by a Chinese herbal formula (Huo-Luo-Xiao-Ling Dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2011</year><volume>2011</volume><fpage>10</fpage><pub-id pub-id-type="publisher-id">642027</pub-id><pub-id pub-id-type="doi">10.1155/2011/642027</pub-id><pub-id pub-id-type="other">2-s2.0-78349285203</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>E.</given-names></name><name><surname>Leong</surname><given-names>K. P.</given-names></name><name><surname>Li</surname><given-names>H. H.</given-names></name><etal/></person-group><article-title>Analysis of a genome-wide association study-linked locus (CCR6) in Asian rheumatoid arthritis</article-title><source><italic>DNA and Cell Biology</italic></source><year>2012</year><volume>31</volume><issue>4</issue><fpage>607</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1089/dna.2011.1350</pub-id><pub-id pub-id-type="other">2-s2.0-84859756829</pub-id><pub-id pub-id-type="pmid">22092173</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Jing</surname><given-names>Y.</given-names></name><name><surname>Lan</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Efficacy of infliximab and methotrexate in the treatment of active rheumatoid arthritis</article-title><source><italic>Journal of Chinese General Practice</italic></source><year>2013</year><volume>16</volume><issue>5</issue><fpage>1711</fpage><lpage>1714</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aslibekyan</surname><given-names>S.</given-names></name><name><surname>Sha</surname><given-names>J.</given-names></name><name><surname>Redden</surname><given-names>D. T.</given-names></name><etal/></person-group><article-title>Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis</article-title><source><italic>Annals of the Rheumatic Diseases</italic></source><year>2014</year><volume>73</volume><issue>4</issue><fpage>785</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204263</pub-id><pub-id pub-id-type="other">2-s2.0-84895446923</pub-id><pub-id pub-id-type="pmid">24291656</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aletaha</surname><given-names>D.</given-names></name><name><surname>Smolen</surname><given-names>J. S.</given-names></name></person-group><article-title>Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints</article-title><source><italic>Arthritis and Rheumatism</italic></source><year>2011</year><volume>63</volume><issue>12</issue><fpage>3702</fpage><lpage>3711</lpage><pub-id pub-id-type="doi">10.1002/art.30634</pub-id><pub-id pub-id-type="other">2-s2.0-82455198746</pub-id><pub-id pub-id-type="pmid">21953215</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandjbakhch</surname><given-names>F.</given-names></name><name><surname>Conaghan</surname><given-names>P. G.</given-names></name><name><surname>Ejbjerg</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state</article-title><source><italic>Journal of Rheumatology</italic></source><year>2011</year><volume>38</volume><issue>9</issue><fpage>2039</fpage><lpage>2044</lpage><pub-id pub-id-type="doi">10.3899/jrheum.110421</pub-id><pub-id pub-id-type="other">2-s2.0-79951497910</pub-id><pub-id pub-id-type="pmid">21885514</pub-id></element-citation></ref><ref id="B16"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lao</surname><given-names>Z. Y.</given-names></name></person-group><article-title>Sinomenine combined with methotrexate in treating rheumatoid arthritis</article-title><source><italic>Chinese Journal of New Drugs and Clinical Remedies</italic></source><year>2000</year><volume>19</volume><issue>4</issue><fpage>254</fpage><lpage>256</lpage></element-citation></ref><ref id="B17"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y. J.</given-names></name></person-group><article-title>Clinical observation small dose methotrexate combined with Zhengqing fengtongning in treating 40 cases of rheumatoid arthritis</article-title><source><italic>Journal of New Chinese Medicine</italic></source><year>2003</year><volume>35</volume><issue>1</issue><fpage>40</fpage><lpage>41</lpage></element-citation></ref><ref id="B18"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S. Y.</given-names></name><name><surname>Lan</surname><given-names>H. M.</given-names></name></person-group><article-title>Summarization on the treatment of 62 cases of rheumatoid arthritis with Zhengqingfengtongning tables and methopterin</article-title><source><italic>Guiding Journal of TCM</italic></source><year>2006</year><volume>12</volume><issue>1</issue><fpage>40</fpage><lpage>41</lpage></element-citation></ref><ref id="B19"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>Z. H.</given-names></name></person-group><article-title>Clinical observation small dose Zhengqingfengtongning combined with methotrexate in treating 30 cases of rheumatoid arthritis</article-title><source><italic>Herald of Medicine</italic></source><year>2006</year><volume>25</volume><issue>1</issue><fpage>37</fpage><lpage>38</lpage></element-citation></ref><ref id="B20"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>H.</given-names></name></person-group><article-title>Clinical observation of effect of 60 cases of rheumatoid arthritis</article-title><source><italic>China Medical Herald</italic></source><year>2010</year><volume>7</volume><issue>13</issue><fpage>p. 218</fpage></element-citation></ref><ref id="B21"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z. S.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name></person-group><article-title>Clinical observation Zhengqingfengtongning sustained release tablet in treating rheumatoid arthritis</article-title><source><italic>Hebei Medical Journal</italic></source><year>2010</year><volume>32</volume><issue>1</issue><fpage>59</fpage><lpage>60</lpage></element-citation></ref><ref id="B22"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y. K.</given-names></name><name><surname>Tu</surname><given-names>S. H.</given-names></name><name><surname>Yong</surname><given-names>Y. H.</given-names></name><etal/></person-group><article-title>Clinical observation of effect of methotrexate combined with Zhengqingfengtongning in treating active rheumatoid arthritis based on syndrome differentiation</article-title><source><italic>Research of Integrated Traditional Chinese and Western Medicine</italic></source><year>2012</year><volume>4</volume><issue>5</issue><fpage>225</fpage><lpage>228</lpage></element-citation></ref><ref id="B23"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F. X.</given-names></name><name><surname>Zhou</surname><given-names>R. H.</given-names></name><name><surname>Shi</surname><given-names>Y. H.</given-names></name><name><surname>Mo</surname><given-names>H. Y.</given-names></name><name><surname>Li</surname><given-names>B. Z.</given-names></name><name><surname>Li</surname><given-names>L. M.</given-names></name></person-group><article-title>Clinical study of Zhengqing Fengtongning combined with methotrexate in treatment of elderly rheumatoid arthritis</article-title><source><italic>Modern Preventive Medicine</italic></source><year>2013</year><volume>40</volume><issue>15</issue><fpage>2944</fpage><lpage>2946</lpage></element-citation></ref><ref id="B24"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y. N.</given-names></name><name><surname>Feng</surname><given-names>X. G.</given-names></name><name><surname>Zhang</surname><given-names>S. L.</given-names></name><etal/></person-group><article-title>Effects of sinomenine combined with methotrexate on rheumatoid arthritis</article-title><source><italic>Practical Pharmacy and Clinical Remedies</italic></source><year>2008</year><volume>11</volume><issue>5</issue><fpage>285</fpage><lpage>287</lpage></element-citation></ref><ref id="B25"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W. Q.</given-names></name></person-group><article-title>Clinical observation of methotrexate combined with Zhengqingfengtongning in treating 120 rheumatoid arthritis</article-title><source><italic>Zhejiang Practical Medicine</italic></source><year>2010</year><volume>15</volume><issue>4</issue><fpage>280</fpage><lpage>281</lpage></element-citation></ref><ref id="B26"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>J. M.</given-names></name></person-group><article-title>Clinical observation of effect of Zhengqingfengtongning combined with methotrexate in treating rheumatoid arthritis</article-title><source><italic>Liaoning Journal of Traditional Chinese Medicine</italic></source><year>2011</year><volume>38</volume><issue>10</issue><fpage>2019</fpage><lpage>2021</lpage></element-citation></ref><ref id="B8"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>E.</given-names></name><name><surname>Chrubasik</surname><given-names>S.</given-names></name></person-group><article-title>Phyto-anti-inflammatories: a systemic review of randomized, placebo- controlled, double-blind trials</article-title><source><italic>Rheumatic Disease Clinics of North America</italic></source><year>2000</year><volume>26</volume><issue>1</issue><fpage>13</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/s0889-857x(05)70117-4</pub-id><pub-id pub-id-type="other">2-s2.0-0033962441</pub-id><pub-id pub-id-type="pmid">10680191</pub-id></element-citation></ref><ref id="B9"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>X.-K.</given-names></name></person-group><article-title>Immunosuppressive and anti-inflammatory activities of sinomenine</article-title><source><italic>International Immunopharmacology</italic></source><year>2011</year><volume>11</volume><issue>3</issue><fpage>373</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2010.11.018</pub-id><pub-id pub-id-type="other">2-s2.0-79952100077</pub-id><pub-id pub-id-type="pmid">21109035</pub-id></element-citation></ref><ref id="B10"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>H.</given-names></name><name><surname>Yamaki</surname><given-names>K.</given-names></name><name><surname>Takano</surname><given-names>H.</given-names></name><name><surname>Inoue</surname><given-names>K.</given-names></name><name><surname>Yanagisawa</surname><given-names>R.</given-names></name><name><surname>Yoshino</surname><given-names>S.</given-names></name></person-group><article-title>Effect of sinomenine on collagen-induced arthritis in mice</article-title><source><italic>Autoimmunity</italic></source><year>2007</year><volume>40</volume><issue>7</issue><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1080/08916930701615159</pub-id><pub-id pub-id-type="other">2-s2.0-39049140211</pub-id><pub-id pub-id-type="pmid">17966044</pub-id></element-citation></ref><ref id="B11"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Buchner</surname><given-names>E.</given-names></name><name><surname>Beitze</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine</article-title><source><italic>International Journal of Immunopharmacology</italic></source><year>1996</year><volume>18</volume><issue>10</issue><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1016/s0192-0561(96)00025-2</pub-id><pub-id pub-id-type="other">2-s2.0-0030268322</pub-id><pub-id pub-id-type="pmid">9080247</pub-id></element-citation></ref><ref id="B12"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Liberati</surname><given-names>A.</given-names></name><name><surname>Teztlaff</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2009</year><volume>151</volume><issue>4</issue><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">19622511</pub-id></element-citation></ref><ref id="B13"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>F. C.</given-names></name><name><surname>Edworthy</surname><given-names>S. M.</given-names></name><name><surname>Bloch</surname><given-names>D. A.</given-names></name><etal/></person-group><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source><italic>Arthritis &#x00026; Rheumatism</italic></source><year>1988</year><volume>31</volume><issue>3</issue><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1002/art.1780310302</pub-id><pub-id pub-id-type="other">2-s2.0-0023945481</pub-id><pub-id pub-id-type="pmid">3358796</pub-id></element-citation></ref><ref id="B14"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadad</surname><given-names>A. R.</given-names></name><name><surname>Moore</surname><given-names>R. A.</given-names></name><name><surname>Carroll</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title><source><italic>Controlled Clinical Trials</italic></source><year>1996</year><volume>17</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(95)00134-4</pub-id><pub-id pub-id-type="other">2-s2.0-0029914622</pub-id><pub-id pub-id-type="pmid">8721797</pub-id></element-citation></ref><ref id="B15"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>1</issue><pub-id pub-id-type="publisher-id">e85008</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085008</pub-id><pub-id pub-id-type="other">2-s2.0-84898645417</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Qi</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>B.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name></person-group><article-title>Sinomenine versus NSAIDs for the treatment of rheumatoid arthritis: a systematic review and meta-analysis</article-title><source><italic>Planta Medica</italic></source><year>2008</year><volume>74</volume><issue>12</issue><fpage>1423</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1081346</pub-id><pub-id pub-id-type="other">2-s2.0-54249103265</pub-id><pub-id pub-id-type="pmid">18683125</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Wong</surname><given-names>Y. F.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>Sinomenine ameliorates arthritis via MMPs, TIMPs, and cytokines in rats</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2008</year><volume>376</volume><issue>2</issue><fpage>352</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.08.153</pub-id><pub-id pub-id-type="other">2-s2.0-52949088275</pub-id><pub-id pub-id-type="pmid">18782565</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kok</surname><given-names>T. W.</given-names></name><name><surname>Yue</surname><given-names>P. Y. K.</given-names></name><name><surname>Mak</surname><given-names>N. K.</given-names></name><name><surname>Fan</surname><given-names>T. P. D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wong</surname><given-names>R. N. S.</given-names></name></person-group><article-title>The anti-angiogenic effect of sinomenine</article-title><source><italic>Angiogenesis</italic></source><year>2005</year><volume>8</volume><issue>1</issue><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s10456-005-2892-z</pub-id><pub-id pub-id-type="other">2-s2.0-24044455371</pub-id><pub-id pub-id-type="pmid">16132613</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>L.</given-names></name><name><surname>Yin</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Sinomenine inhibits primary CD4<sup>+</sup> T-cell proliferation via apoptosis</article-title><source><italic>Cell Biology International</italic></source><year>2007</year><volume>31</volume><issue>8</issue><fpage>784</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1016/j.cellbi.2007.01.035</pub-id><pub-id pub-id-type="other">2-s2.0-34248523197</pub-id><pub-id pub-id-type="pmid">17383204</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L. Y.</given-names></name><name><surname>Wang</surname><given-names>X. F.</given-names></name><name><surname>Tan</surname><given-names>J. T.</given-names></name><etal/></person-group><article-title>Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis</article-title><source><italic>Journal of Cellular and Molecular Medicine</italic></source><year>2015</year><volume>18</volume><issue>11</issue><fpage>2213</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12353</pub-id><pub-id pub-id-type="other">2-s2.0-84911108527</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>B.</given-names></name><name><surname>Yu</surname><given-names>J. T.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Sinomenine suppresses collagen-induced arthritis by reciprocal modulation of regulatory T cells and Th17 cells in gut-associated lymphoid tissues</article-title><source><italic>Molecular Immunology</italic></source><year>2015</year><volume>65</volume><issue>1</issue><fpage>94</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2015.01.014</pub-id><pub-id pub-id-type="other">2-s2.0-84921957794</pub-id><pub-id pub-id-type="pmid">25656802</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Process of searching and screening studies.</p></caption><graphic xlink:href="ECAM2015-910376.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Risk of bias summary and risk of bias graph.</p></caption><graphic xlink:href="ECAM2015-910376.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Analysis of the total effect of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Analysis of RF of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Analysis of ESR of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Analysis of CRP of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Analysis of duration of morning stiffness of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.007"/></fig><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Analysis of swollen joint count of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.008"/></fig><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Analysis of tender joint count of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.009"/></fig><fig id="fig10" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Analysis of adverse effects of ZQFTN combined with MTX and MTX only for the treatment of RA ((1) study, first name of the first author, publishing year, and the number of studies; (2) experimental: the group of MTX combined with ZQFTN; control: the group of MTX only; (3) <italic>I</italic>-squared and <italic>P</italic> are the criterion of heterogeneity test; &#x025c6;: pooled relative risk; -&#x025a0;-: relative risk and 95 confidence interval).</p></caption><graphic xlink:href="ECAM2015-910376.010"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of the included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Author, year</th><th align="center" colspan="2" rowspan="1">Sample size</th><th align="center" colspan="2" rowspan="1">
Intervention methods</th><th align="center" rowspan="1" colspan="1">Duration</th><th align="center" rowspan="2" colspan="1">Outcomes</th></tr><tr><th align="center" rowspan="1" colspan="1">EG</th><th align="center" rowspan="1" colspan="1">CG</th><th align="center" rowspan="1" colspan="1">EG</th><th align="center" rowspan="1" colspan="1">CG</th><th align="center" rowspan="1" colspan="1">(wks)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lao 2000 [<xref rid="B16" ref-type="bibr">8</xref>]</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">ZQFTN 20&#x02013;40&#x02009;mg&#x02009;tid, MTX 7.5&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TE, TJC, SJC, DMS, RF, ESR, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Wu 2003 [<xref rid="B17" ref-type="bibr">9</xref>]</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">ZQFTN 40&#x02009;mg&#x02009;tid, MTX 7.5&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TE, TJC, SJC, DMS, RF, ESR, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
Sun and Lan 2006 [<xref rid="B18" ref-type="bibr">10</xref>]</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">ZQFTN 120&#x02009;mg&#x02009;qd, MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">TE, RF, ESR, CRP, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ji and Zhu 2006 [<xref rid="B19" ref-type="bibr">11</xref>]</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">ZQFTN 20&#x02013;40&#x02009;mg&#x02009;tid, MTX 7.5&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TE, TJC, SJC, DMS, RF, ESR, CRP, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ding 2010 [<xref rid="B20" ref-type="bibr">12</xref>]</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">ZQFTN 20&#x02013;40&#x02009;mg&#x02009;tid, MTX 7.5&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Huang and Wang 2010 [<xref rid="B21" ref-type="bibr">13</xref>]&#x02009;</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">ZQFTN 60&#x02009;mg&#x02009;bid, MTX 7.5&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TE, TJC, SJC, DMS, RF, ESR, CRP, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Xia et al. 2012 [<xref rid="B22" ref-type="bibr">14</xref>]</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">ZQFTN 60&#x02009;mg&#x02009;tid, MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TE, TJC, SJC, DMS, RF, ESR, CRP, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Zhu et al. 2013 [<xref rid="B23" ref-type="bibr">15</xref>]</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">ZQFTN 60&#x02009;mg&#x02009;bid, MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">TE, TJC, SJC, DMS, ESR, CRP, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Li et al. 2008 [<xref rid="B24" ref-type="bibr">16</xref>]</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">ZQFTN 120&#x02009;mg&#x02009;bid, MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 15&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">TE, DMS, RF, ESR, CRP, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Wang 2010 [<xref rid="B25" ref-type="bibr">17</xref>]</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">ZQFTN 120&#x02009;mg&#x02009;bid, MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">TE, DMS, RF, ESR, CRP, AE</td></tr><tr><td align="center" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lu and Su 2011 [<xref rid="B26" ref-type="bibr">18</xref>]</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">ZQFTN 120&#x02009;mg&#x02009;bid, MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">MTX 10&#x02009;mg&#x02009;qw</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TE, TJC, RF, ESR, CRP, AE</td></tr></tbody></table><table-wrap-foot><fn><p>Note: ZQFTN: Zhengqing Fengtongning; EG: experimental group; CG: control group; TE: total effect; TJC: tender joint count; SJC: swollen joint count; DMS: duration of morning stiffness; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; AE: adverse effect.</p></fn></table-wrap-foot></table-wrap></floats-group></article>